FDA Brief

Warning letters Drugs

FDA warning letter to

Jabil Inc.

High riskIssued Aug 27Posted Sep 1Center for Drug Evaluation and Research (CDER)

FDA warned Jabil Inc. after an inspection found inadequate investigations of mold and sterility failures at its sterile injectable contract manufacturer.

What happened

FDA inspected Pharmaceutics International, Inc. (a Jabil Company), a sterile injectable contract manufacturer in Cockeysville, MD, from February 23 to March 6, 2026. FDA found inadequate investigations of a sterility test failure and repeated mold recoveries in Grade A filling areas, plus quality-unit, aseptic airflow, environmental monitoring, and facility maintenance deficiencies. The letter says the company's drug products are adulterated because manufacturing does not conform to CGMP.

What FDA found

  1. The company did not thoroughly investigate a sterility test failure or repeated mold recoveries in its ISO 5 (Grade A) filling areas, and its corrective actions were inadequate.

    21 CFR 211.192
  2. The quality unit lacked adequate oversight of sterile manufacturing and did not ensure required controls were followed.

    21 CFR 211.22(d)
  3. Batch records documented about 12 aseptic interventions when records indicated about 200, so critical interventions were not recorded.

    21 CFR 211.188
  4. Disinfectant efficacy studies did not adequately represent the microbes found in the facility.

    21 CFR 211.42(c)(10)(v)
  5. The company did not perform process validation after adding a new production step and did not provide stability data.

    21 CFR 211.100(a)
  6. Smoke studies, environmental monitoring, and facility maintenance were inadequate, including peeling paint and plastic debris in classified areas.

    21 CFR 211.113(b) and 21 CFR 211.58

What FDA wants

FDA tells the company to address the violations promptly and provide comprehensive assessments and remediation plans for investigations, the quality unit, contamination control, environmental monitoring, and facilities. FDA also recommends a CGMP consultant and a teleconference; the letter does not state a specific response deadline.

Who should pay attention

  • brands that buy sterile injectables from this contract manufacturer
  • other sterile injectable manufacturers
  • quality teams managing contract manufacturing suppliers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  2. Baxter International Inc.

    Baxter's Round Lake injectable drug plant violated CGMP (manufacturing quality rules), with cephalosporin cross-contamination and sterile processing failures.

    High risk
  3. Fresenius Kabi USA LLC

    FDA warns Fresenius Kabi USA over manufacturing failures for sterile injectables at Melrose Park, including endotoxin contamination and media fill failures.

    High risk
  4. Eugia Pharma Specialities Limited

    FDA warned Eugia Pharma Specialities that flawed aseptic line design and poor aseptic practices at its Kolthur Village plant risk contaminating sterile injectables.

    High risk